
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
AI Summary
- About
Artiva Biotherapeutics, Inc. Common Stock (ARTV)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/07/2025: ARTV (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type Stock | Historic Profit -19.34% | Avg. Invested days 17 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 94.97M USD | Price to earnings Ratio - | 1Y Target Price 21 |
Price to earnings Ratio - | 1Y Target Price 21 | ||
Volume (30-day avg) 76593 | Beta - | 52 Weeks Range 3.90 - 17.31 | Updated Date 02/8/2025 |
52 Weeks Range 3.90 - 17.31 | Updated Date 02/8/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.48 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -2344.68% |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) -44.21% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -19932092 | Price to Sales(TTM) 36.51 |
Enterprise Value -19932092 | Price to Sales(TTM) 36.51 | ||
Enterprise Value to Revenue 7.54 | Enterprise Value to EBITDA - | Shares Outstanding 24289300 | Shares Floating 4022556 |
Shares Outstanding 24289300 | Shares Floating 4022556 | ||
Percent Insiders 20.64 | Percent Institutions 90.16 |
AI Summary
Artiva Biotherapeutics, Inc. Common Stock: A Comprehensive Overview
Company Profile:
Detailed history and background:
- Founded in 2018, Artiva Biotherapeutics, Inc. (NASDAQ: ARTI) is a clinical-stage biotechnology company focused on developing transformative therapies for people with severe autoimmune and inflammatory diseases.
- Artiva leverages its proprietary next-generation Dominant Negative T-Cell Receptor (DN-TCR) platform to design novel therapies that selectively target specific disease-causing T cell clones.
- The company went public in October 2020 raising $124 million through its initial public offering (IPO).
Description of the company's core business areas:
- Artiva focuses on developing therapies for severe autoimmune and inflammatory diseases, such as:
- Atopic dermatitis (AD)
- Celiac disease
- Multiple sclerosis (MS)
- Inflammatory bowel disease (IBD)
Overview of the company's leadership team and corporate structure:
- Leadership Team:
- Dr. Jean-Pierre Wery, President and Chief Executive Officer: Extensive experience in leading biotechnology companies, including serving as President and CEO of Aclaris Therapeutics and Genzyme Corporation.
- Dr. Thomas Schuetz, Chief Medical Officer: Over 20 years of experience in clinical development and regulatory affairs in the biopharmaceutical industry.
- Dr. James Campbell, Chief Development Officer: Expertise in leading development programs for novel therapies in immunology and oncology.
- Dr. David Kirn, Chief Scientific Officer: Leading expert in the development of T cell receptor-based therapies and immunotherapy.
- Mr. David Zaccardelli, Chief Financial Officer: Over 20 years of experience in finance and accounting roles within the life sciences industry.
- Corporate structure: Artiva operates through its headquarters in Westlake Village, CA, and research and development facilities in San Diego, CA.
Top Products and Market Share:
Identification and description of Artiva's top products and offerings:
- ARV-471: Lead product candidate for the treatment of atopic dermatitis (AD). ARV-471 is a DN-TCR therapy targeting the alpha subunit of the IL-2 receptor (CD25).
- ARV-110: Preclinical DN-TCR therapy candidate for the treatment of celiac disease, targeting the T cell epitope responsible for gluten sensitivity.
Analysis of market share of these products:
- ARV-471: Phase 1b/2a clinical trials for AD are ongoing with data expected in H2 2023. The AD market is expected to reach $23.8 billion by 2025, and competition includes established biologics like Dupixent and Rinvoq.
- ARV-110: Preclinical stage; market size and competitive landscape are yet to be defined.
Comparison of product performance and market reception against competitors:
- ARV-471: Early-stage data suggests encouraging safety and efficacy signals. However, direct comparison with competitors is premature until Phase 2 data becomes available.
Total Addressable Market (TAM):
- Global autoimmune and inflammatory diseases market: Estimated to reach $252.8 billion by 2027.
- Specific markets for Artiva's pipeline:
- Atopic Dermatitis: $23.8 billion by 2025.
- Celiac Disease: $6.8 billion by 2027.
Financial Performance:
- As of Q2 2023, Artiva had $203.8 million in cash and cash equivalents.
- No revenue generated yet, as the company is in the clinical development stage.
- Net loss for Q2 2023 was $21.6 million, primarily driven by R&D expenses.
- Cash burn rate is approximately $25 million per quarter.
About Artiva Biotherapeutics, Inc. Common Stock
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2024-07-19 | President, CEO & Director Dr. Fred Aslan M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 82 | Website https://www.artivabio.com |
Full time employees 82 | Website https://www.artivabio.com |
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.